Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP675154.RA1VP4Mr9hnL_1q3KHXdHeT5KEiGFZ3DWbbh52x0B82tc130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP675154.RA1VP4Mr9hnL_1q3KHXdHeT5KEiGFZ3DWbbh52x0B82tc130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP675154.RA1VP4Mr9hnL_1q3KHXdHeT5KEiGFZ3DWbbh52x0B82tc130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP675154.RA1VP4Mr9hnL_1q3KHXdHeT5KEiGFZ3DWbbh52x0B82tc130_provenance.
- NP675154.RA1VP4Mr9hnL_1q3KHXdHeT5KEiGFZ3DWbbh52x0B82tc130_assertion description "[The aim of this study was to evaluate the response and resistance of cases to chronic myeloid leukemia (CML) therapy with tyrosine kinase (TK) inhibitors (imatinib mesylate) and to search for mutations in the breakpoint cluster region (BCR)-Abelson murine leukemia (ABL) kinase domain prior to and during therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP675154.RA1VP4Mr9hnL_1q3KHXdHeT5KEiGFZ3DWbbh52x0B82tc130_provenance.
- NP675154.RA1VP4Mr9hnL_1q3KHXdHeT5KEiGFZ3DWbbh52x0B82tc130_assertion evidence source_evidence_literature NP675154.RA1VP4Mr9hnL_1q3KHXdHeT5KEiGFZ3DWbbh52x0B82tc130_provenance.
- NP675154.RA1VP4Mr9hnL_1q3KHXdHeT5KEiGFZ3DWbbh52x0B82tc130_assertion SIO_000772 19943786 NP675154.RA1VP4Mr9hnL_1q3KHXdHeT5KEiGFZ3DWbbh52x0B82tc130_provenance.
- NP675154.RA1VP4Mr9hnL_1q3KHXdHeT5KEiGFZ3DWbbh52x0B82tc130_assertion wasDerivedFrom befree-20140225 NP675154.RA1VP4Mr9hnL_1q3KHXdHeT5KEiGFZ3DWbbh52x0B82tc130_provenance.
- NP675154.RA1VP4Mr9hnL_1q3KHXdHeT5KEiGFZ3DWbbh52x0B82tc130_assertion wasGeneratedBy ECO_0000203 NP675154.RA1VP4Mr9hnL_1q3KHXdHeT5KEiGFZ3DWbbh52x0B82tc130_provenance.
- befree-20140225 importedOn "2014-02-25" NP675154.RA1VP4Mr9hnL_1q3KHXdHeT5KEiGFZ3DWbbh52x0B82tc130_provenance.